CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Vista trial begins dosing in precision cancer vaccine study

Trial StartVistaPositive
AI Analysis

Summary

Infinitopes announced the beginning of patient dosing in the Vista trial, a first-in-human study evaluating its infinitopes therapeutic platform for precision cancer vaccines.

Clinical Trial Data

Phase

Phase_1

Importance:5/10
Sentiment:
0.30
cancer vaccineprecision medicinefirst-in-humantherapeutic platformclinical trial
Related Companies

Read the original article

Published by PharmaTimes on July 30, 2026 11:09 AM

Read Original